AS1404 : Antisoma : vascular disrupting agent

Preliminary Phase II Data for AS1404 in Lung Cancer (Antisoma)
Press release announcing preliminary findings from an ongoing phase II trial of AS1404 in lung cancer. Preliminary data from 47 of 71 enrolled patients found those receiving AS1404 in addition to chemotherapy showed a higher frequency of tumor response (43.5% vs 33.3%) and a lower frequency of progressive disease (8.7% vs 33.3%) than those receiving chemotherapy alone. [10/05]